A National Registry on Chinese Patients With Lymphangioleiomyomatosis

Pulmonary Function Clinical Trial

Official title: A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA)

Status Recruiting

Clinical Trial Summary

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China.

Clinical Trial Description

Pulmonary lymphangioleiomyomatosis (LAM), a disease characterized by diffuse cystic changes in the lung, is a rare disorder that affects almost exclusively women. The main objectives of this study are to accurately evaluate the prevalence of LAM, the status of disease, the diagnosis and treatment, the quality of care, and the health related outcomes in China. This is a register study lasting 4 years, aims to raise 800 subjects. Primary endpoint is the annual change of forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) in pulmonary function tests. ;

Related Conditions & MeSH terms

• Lymphangioleiomyomatosis
• Pulmonary Function

• NCT number: NCT03193892
• Study type: Observational [Patient Registry]
• Source: Peking Union Medical College Hospital
• Contact: Kai-Feng Xu, M.D.
• Phone: 86-10-69155039
• Email: xukf@pumch.cn
• Status: Recruiting
• Start date: January 1, 2017
• Completion date: October 1, 2026